<DOC>
	<DOCNO>NCT01768975</DOCNO>
	<brief_summary>The purpose trial investigate efficacy safety OLT1177 Gel subject moderate severe pain associate osteoarthritis knee follow cessation pain therapy .</brief_summary>
	<brief_title>Phase 2 Efficacy Trial OLT1177 Gel Subjects With Moderate Severe Pain Associated With OA Knee</brief_title>
	<detailed_description>This randomize , double-blind , vehicle-controlled , repeat-dose , multi-center Phase 2 efficacy safety clinical trial subject moderate severe pain associate osteoarthritis knee . Eighty-four subject , randomize 2:1 ratio ( OLT1177 Gel vehicle control ) receive 40 dos Investigational Drug ( 56 subject OLT1177 Gel 28 subject vehicle control ) 14 consecutive day give 3 time per day ( 4 mL per dose , TID Days 1 - 13 one dose administer Day 14 , assume TID Day 1 ) safety data collect Day 28 . Subjects moderate severe pain associate osteoarthritis knee evaluate twice eligibility : 1 ) Screening visit ; 2 ) Baseline ( Day 0 ) visit , 7-day washout period pain medication except trial provide Rescue Medication ( 500 mg/dose acetaminophen ) experience unacceptable pain washout 14-day treatment period . Subjects encouraged take pain medication 7-day washout period ; however , first 5 day allow take Rescue Medication . No pain medication , include Rescue Medication , allow 2-day pain intensity assessment period within 48 hour Baseline ( Day 0 ) , Day 7 Day 14 visit . Subjects ask record report level pain different time point throughout 14-day trial .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Age 35 80 Subjects childbearing potential partner must use effective contraception OA base ACR criterion OA knee ≥ 6 month prior Screening OA knee pain require NSAID therapy ≥ 15 day Pain Movement contralateral knee ≤ 20 mm Radiographic evidence OA KellgrenLawrence score 2 3 take 6 month prior Screening Moderate severe OA pain define POM score 50 mm 90 mm Baseline WOMAC pain subscale score ≥ 9 No change physical activity and/or therapy past 3 month Provide write informed consent comply trial Use Rescue Medication pain medication 48 hour prior Baseline visit Inflammatory skin condition target knee Extreme pain target knee characterize POM score &gt; 90 mm Mild pain target knee , characterize POM score &lt; 50 mm &gt; 30 mm POM score variability Days 2 1 Baseline visit Baseline POM score &gt; 20 mm contralateral knee significant joint general pain Baseline visit Excessive effusion target knee Heat and/or redness comparison contralateral knee Knockkneed bowlegged define valgus varus deformity ≥ 15 degree Acute chronic injury OA Radiographic evidence OA KellgrenLawrence score 0 , 1 4 Open surgery target knee within last year Arthroscopic surgery target knee within last 6 month Surgery target knee require insertion medical device surgical hardware Use prohibit concomitant medications/therapies 7day washout period plan use 14day treatment period include : 1 . Prescription medication treat pain , OTC natural supplement 2 . Muscle relaxant unless stable dose ≥ 30 day prior Screening 3 . Nutraceuticals unless stable dose ≥ 3 month prior Screening 4 . Sedative hypnotic unless stable dose ≥ 30 day prior Screening 5 . Devices therapeutic treatment knee pain ambulation 6 . Systemic corticosteroid 7 . Other Investigational Drugs 8 . Chemotherapeutic drug 9 . Immunotherapy 10 . Topical product apply target knee 11 . Cyclosporine ( except ophthalmic ) , lithium , methotrexate 12 . Antidepressants medication act central nervous system , unless stable dose depression ≥ 3 month prior Screening 13 . Narcotics previous history chronic narcotic use 14 . Rescue Medication within 48 hour Baseline , Day 7 Day 14 visit Intraarticular steroid target knee within previous 3 month joint within previous 30 day Intraarticular hyaluronate within previous 6 month joint within previous 30 day Systemic corticosteroid within prior month Documented history inflammatory joint disease BMI 35 Uncontrolled psychiatric condition Cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological neurological disease prior surgery Uncontrolled hypertension Diabetes HbA1c level &gt; 8 Known positive HIV , Hepatitis B surface antigen ( HBsAg ) antibodies Hepatitis C Virus ( HCV ) Cancer within past 5 year , except treat basal cell squamous cell carcinoma skin Any medical condition , diseases prior surgery Interventional and/or surgical procedure 28 day follow randomization Change level physical activity 28 day follow randomization Active infection fever ≥ 38°C within 3 day Baseline visit Known sensitivity Investigational Drug Women plan become pregnant 28day trial Participation Investigational Drug device trial within 30day prior Baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Knee</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>OA</keyword>
	<keyword>Knee pain</keyword>
	<keyword>Moderate pain</keyword>
	<keyword>Severe pain</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Randomized</keyword>
	<keyword>Topical</keyword>
	<keyword>Gel</keyword>
	<keyword>Olatec</keyword>
	<keyword>OLT1177</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Analgesic</keyword>
</DOC>